We could not find any results for:
Make sure your spelling is correct or try broadening your search.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, ... BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology. Show more
RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2024 financial...
RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO®...
–Presentations will demonstrate high adherence and persistence, sustained attack reductions and patient preference for oral, once-daily ORLADEYO for hereditary angioedema– RESEARCH TRIANGLE PARK...
RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors...
—Potential best-in-class targeted treatment for Netherton syndrome is company’s first protein therapeutic to advance to the clinic— —Initial data from trial expected by end of 2025— RESEARCH...
RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS...
INTENDED FOR CANADIAN AUDIENCES ONLY TORONTO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it successfully completed negotiations with...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.09 | 1.20805369128 | 7.45 | 7.715 | 7.24 | 1238617 | 7.52037498 | CS |
4 | -0.61 | -7.48466257669 | 8.15 | 8.15 | 7.01 | 1584811 | 7.47861958 | CS |
12 | -0.33 | -4.19313850064 | 7.87 | 8.88 | 6.49 | 1958848 | 7.72895049 | CS |
26 | 3.11 | 70.2031602709 | 4.43 | 8.88 | 4.03 | 2757768 | 6.63657888 | CS |
52 | 1.84 | 32.2807017544 | 5.7 | 8.88 | 4.03 | 3163731 | 6.07154265 | CS |
156 | -6.79 | -47.3831123517 | 14.33 | 19.99 | 4.03 | 3184602 | 9.472302 | CS |
260 | 5.14 | 214.166666667 | 2.4 | 19.99 | 1.38 | 4180792 | 7.99053894 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions